Inhalation Sciences Sweden AB (publ) (XSAT:ISAB)

Sweden · Delayed Price · Currency is SEK

0.1425

+0.0025 (1.79%)

At close: Aug 26, 2026

-68.75% (1Y)

Market Cap	7.30M -88.9%
Revenue (ttm)	8.30M +55.0%
Net Income	-8.56M
EPS	-0.20
Shares Out	51.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	96,769
Open	0.1395
Previous Close	0.1400
Day's Range	0.1395 - 0.1455
52-Week Range	0.1300 - 0.5850
Beta	-0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About XSAT:ISAB

Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research in Sweden. The company offers PreciseInhale, a laboratory system that allows scientists to measure how inhaled particles act in lungs and affect the health; DissolvIt, which enables in vitro simulation of dissolution and absorption of respirable particles in the lung epithelium; XposeALI, a 3D cell exposure module that combines aerosol capability with 3D cell models cultured at an air liquid interface; Nose-only inhalation, a standard method of exp... [Read more]

Industry Surgical and Medical Instruments and Apparatus

Founded 2004

Employees 5

Stock Exchange Spotlight Stock Market

Ticker Symbol ISAB

Full Company Profile

Financial Performance

In 2025, XSAT:ISAB's revenue was 3.04 million, a decrease of -72.47% compared to the previous year's 11.05 million. Losses were -10.16 million, 97.4% more than in 2024.

Financial Statements

News

Inhalation Sciences Sweden AB Quarterly report: Q2 2026

Inhalation Sciences Sweden AB has published its Q2 2026 quarterly earnings report on August 24, 2026.

3 days ago - Filings

Inhalation Sciences Sweden AB Transcript: Transcript

Q1 2026 revenue surpassed all of 2025, driven by new orders and strong pipeline activity. The company is progressing with its M&A process, aiming for completion before summer 2026, while navigating new U.S. regulatory challenges and leveraging successful marketing campaigns.

17 days ago - Transcripts

Inhalation Sciences Sweden AB Transcript: Transcript

Q4 sales exceeded SEK 5 million, with a strong order backlog for 2026 and increased pipeline activity following FDA endorsement. The ongoing M&A process aims for completion in H1 2026, while marketing efforts continue to generate leads and orders.

17 days ago - Transcripts